Passage BIO, Inc. (PASG) intrinsic value & 10-year financials
Passage BIO, Inc. (PASG) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.50
- Market cap
- $11.1M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -71.6%
- Free cash flow (FY2025)
- —
PASG 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$45.5M | -$14.35 | — | — | -256.9% |
| FY2024 | — | -$64.8M | -$1.07 | -$48.0M | — | -89.1% |
| FY2023 | — | -$102.1M | -$1.86 | — | — | -67.3% |
| FY2022 | — | -$136.1M | -$2.50 | — | — | -71.4% |
| FY2021 | — | -$185.4M | -$3.48 | — | — | -59.5% |
| FY2020 | — | -$112.2M | -$2.91 | — | — | -90.3% |
| FY2019 | — | -$45.6M | — | — | — | 133.4% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Passage BIO, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Passage BIO, Inc. has historically struggled to out-earn its cost of capital, averaging just -35.3% ROIC.
Passage BIO, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Passage BIO, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.